Clinical Trials
2 trialsNCT07570173 2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT06043323 2026-05-06
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting